In light of our results, which suggest a protective role of SMAD2/3 phosphorylation, inhibition of active HTRA1 or suppression of HTRA1 transcription by interfering with Gtf2i β/δ binding should be advocated for AMD patients with the in/del haplotype. The gene discussed is HTRA1; the disease is age-related macular degeneration.